Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 257

1.

Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.

Buynak R, Shapiro DY, Okamoto A, Van Hove I, Rauschkolb C, Steup A, Lange B, Lange C, Etropolski M.

Expert Opin Pharmacother. 2010 Aug;11(11):1787-804. doi: 10.1517/14656566.2010.497720. Erratum in: Expert Opin Pharmacother. 2010 Nov;11(16):2773.

PMID:
20578811
2.

Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.

Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, Steup A, Lange B, Rauschkolb C, Haeussler J.

Clin Drug Investig. 2010;30(8):489-505. doi: 10.2165/11533440-000000000-00000.

PMID:
20586515
4.

Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain.

Biondi DM, Xiang J, Etropolski M, Moskovitz B.

J Opioid Manag. 2015 Sep-Oct;11(5):393-403. doi: 10.5055/jom.2015.0289.

PMID:
26535967
5.

A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain.

Daniels S, Casson E, Stegmann JU, Oh C, Okamoto A, Rauschkolb C, Upmalis D.

Curr Med Res Opin. 2009 Jun;25(6):1551-61. doi: 10.1185/03007990902952825. Erratum in: Curr Med Res Opin. 2009 Jun;25(6):1561. Dosage error in article text.

PMID:
19445652
6.

Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study.

Hale M, Upmalis D, Okamoto A, Lange C, Rauschkolb C.

Curr Med Res Opin. 2009 May;25(5):1095-104. doi: 10.1185/03007990902816970 .

PMID:
19301989
7.

Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain.

Imanaka K, Tominaga Y, Etropolski M, van Hove I, Ohsaka M, Wanibe M, Hirose K, Matsumura T.

Curr Med Res Opin. 2013 Oct;29(10):1399-409. doi: 10.1185/03007995.2013.831816. Epub 2013 Aug 23.

PMID:
23937387
8.

Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.

Etropolski M, Kelly K, Okamoto A, Rauschkolb C.

Adv Ther. 2011 May;28(5):401-17. doi: 10.1007/s12325-011-0018-0. Epub 2011 Apr 13.

PMID:
21494892
9.

A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain.

Daniels SE, Upmalis D, Okamoto A, Lange C, Häeussler J.

Curr Med Res Opin. 2009 Mar;25(3):765-76. doi: 10.1185/03007990902728183 .

PMID:
19203298
10.

Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.

Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, Rauschkolb C.

Curr Med Res Opin. 2011 Jan;27(1):151-62. doi: 10.1185/03007995.2010.537589.

PMID:
21162697
11.

Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.

Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Lange B, Dogan C, Etropolski MS, Eerdekens M.

Pain Physician. 2014 Jul-Aug;17(4):329-43.

13.

A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain.

Etropolski M, Lange B, Goldberg J, Steup A, Rauschkolb C.

J Opioid Manag. 2013 Sep-Oct;9(5):343-56. doi: 10.5055/jom.2013.0177.

PMID:
24353047
15.

Evaluation of study discontinuations with tapentadol inmmediate release and oxycodone immediate release in patients with low back or osteoarthritis pain.

Vorsanger G, Xiang J, Okamoto A, Upmalis D, Moskovitz B.

J Opioid Manag. 2010 May-Jun;6(3):169-79.

PMID:
20642246
16.

Efficacy of tapentadol ER for managing moderate to severe chronic pain.

Afilalo M, Morlion B.

Pain Physician. 2013 Jan;16(1):27-40. Review.

17.

Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.

Biondi D, Xiang J, Benson C, Etropolski M, Moskovitz B, Rauschkolb C.

Pain Physician. 2013 May-Jun;16(3):E237-46.

18.

Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.

Steigerwald I, Müller M, Davies A, Samper D, Sabatowski R, Baron R, Rozenberg S, Szczepanska-Szerej A, Gatti A, Kress HG.

Curr Med Res Opin. 2012 Jun;28(6):911-36. doi: 10.1185/03007995.2012.679254. Epub 2012 May 9.

PMID:
22443293
19.

Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.

Merchant S, Provenzano D, Mody S, Ho KF, Etropolski M.

J Opioid Manag. 2013 Jan-Feb;9(1):51-61. doi: 10.5055/jom.2013.0147.

PMID:
23709304
20.

A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy.

Vinik AI, Shapiro DY, Rauschkolb C, Lange B, Karcher K, Pennett D, Etropolski MS.

Diabetes Care. 2014 Aug;37(8):2302-9. doi: 10.2337/dc13-2291. Epub 2014 May 21.

PMID:
24848284
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk